Adrian Senderowicz Sells 27,000 Shares of PBYI
Adrian Senderowicz sold shares of PBYI for $194,400 in a planned transaction.
Key Points
- Adrian Senderowicz sold 27,000 shares of PBYI at $7.20 per share on June 12, 2026, for a total of $194,400.
- PBYI's stock was trading at $7.33, with insiders including Dorval Allison and Brian Stuglik also selling shares.
- Acadian Asset Management and Vanguard Capital Management increased their holdings in PBYI, while BlackRock reduced its stake.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Adrian Senderowicz, associated with PBYI, sold 27,000 shares on June 12, 2026, in a planned transaction. The shares were sold at an average price of $7.20 each, bringing the total transaction value to $194,400.
Insider Buying and Selling at Puma Biotechnology, Inc.
On June 12, 2026, several insiders at PBYI sold shares in planned transactions. Dorval Allison sold 11,610 shares at $7.20 each, and Brian Stuglik sold 8,100 shares at the same price. Adrian Senderowicz's sale involved 27,000 shares, also at $7.20 per share. Additionally, Jay Moyes sold 22,000 shares at $7.22, while Troy Edward Wilson sold 10,800 shares at $7.20. Jay Moyes also made a purchase of 27,000 shares on June 11, 2026, in a non-planned transaction.
Other Institutional Activity in PBYI
In recent institutional activity, Acadian Asset Management added 16,936 shares, bringing its total to 2,041,759 shares valued at approximately $13.04 million. Vanguard Capital Management significantly increased its holdings by 1,817,681 shares, reaching a total of 1,817,681 shares worth about $11.61 million. Meanwhile, BlackRock reduced its stake by 43,636 shares, holding 3,598,952 shares valued at $22.99 million. Renaissance Technologies also decreased its position by 181,400 shares, leaving it with 1,942,413 shares valued at $12.41 million.
Analysts Set New Price Targets
Analyst firm H.C. Wainwright has consistently reiterated a 'buy' rating for PBYI, maintaining a price target of $7.00 as recently as February 28, 2025. In contrast, TD Cowen maintained a 'hold' rating with a $4.00 target on May 20, 2024, and Barclays maintained a 'sell' rating with a $2.00 target on May 3, 2024.
Bottom Line
Adrian Senderowicz's sale of PBYI shares is part of a broader insider selling trend observed on June 12, 2026. While insider transactions can provide insight into executive sentiment, they are not definitive indicators of future stock performance. Investors often monitor such transactions alongside institutional activities and analyst ratings to gauge market sentiment and potential stock movements.
Get Puma Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PBYI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.